Baseline hepatitis B surface antigen and cirrhosis predict extended interferon therapy in chronic hepatitis B: A retrospective study

doi:10.3748/wjg.v32.i12.116287

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 12

This Article

(42)

(32)

(0)

(13)

(781)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Mar 28, 2026; 32(12): 116287
Published online Mar 28, 2026. doi: 10.3748/wjg.v32.i12.116287

Full Size Figure Download Figure

Figure 6 Subgroup analyses stratified by gender, age, baseline hepatitis B envelope antigen, baseline hepatitis B virus DNA, and baseline alanine aminotransferase in the training and validation cohorts. The relationships of both baseline hepatitis B surface antigen (HBsAg) and liver cirrhosis with extended course interferon (≥ 48 weeks) were consistent with the primary outcome in most subgroups. Furthermore, no significant interactions were observed concerning the association with extended course interferon (≥ 48 weeks). A and B: Baseline HBsAg: Training cohort (A); Validation cohort (B); C and D: Cirrhosis: Training cohort (C); Validation cohort (D). OR: Odds ratio; CI: Confidence interval; HBeAg: Hepatitis B envelope antigen; HBV: Hepatitis B virus; ALT: Alanine aminotransferase.

Citation: Yan F, Xue XL, Guo Y, Zhang QR, You RR, Shang J, Wu XP, Geng JW, Gao XH, Ye Q, Liang J, Wang XY, Zeng JY, Chen J, Lin YC, Chen XY, Du Q, Yin WL, Liu L, Wang F, Xu BG, Zhang WH, Xiang HL. Baseline hepatitis B surface antigen and cirrhosis predict extended interferon therapy in chronic hepatitis B: A retrospective study. World J Gastroenterol 2026; 32(12): 116287
URL: https://www.wjgnet.com/1007-9327/full/v32/i12/116287.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i12.116287

Yan F, Xue XL, Guo Y, Zhang QR, You RR, Shang J, Wu XP, Geng JW, Gao XH, Ye Q, Liang J, Wang XY, Zeng JY, Chen J, Lin YC, Chen XY, Du Q, Yin WL, Liu L, Wang F, Xu BG, Zhang WH, Xiang HL. Baseline hepatitis B surface antigen and cirrhosis predict extended interferon therapy in chronic hepatitis B: A retrospective study. World J Gastroenterol 2026; 32(12): 116287 [DOI: 10.3748/wjg.v32.i12.116287]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.